Description: Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.
Home Page: www.nanexa.com
Virdings AllE 32B
Uppsala,
75450
Sweden
Phone:
46 18 10 03 00
Officers
| Name | Title |
|---|---|
| Mr. David Westberg | Chief Exec. Officer |
| Mr. Marten Rooth | Co-Founder, Head of R&D Atomic Layer Deposition, CTO and Director |
| Mr. Bengt Gustavsson M.Sc. | Medical Director & Director |
| Mr. Otto Skolling M.Sc | Director Bus. Devel. & Director |
| Mr. Anders Johansson | Co-Founder & Head of Intellectual Property |
| Mr. Björn Svanström | Chief Financial Officer |
| Mr. Mikael Asp | Head of QA & Expert |
| Mr. Joel Hellrup | Head of Pharmaceutical R&D |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6807 |
| Price-to-Sales TTM: | 3.3365 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 19 |